Statin use and cancer risk: a comprehensive review
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: HMG-CoA inhibitors (statins), a class of drugs that reduce cholesterol, are used to manage and prevent coronary heart disease. They are among the most commonly prescribed drugs worldwide. Contrary to early concerns over the carcinogenicity of statins, a growing body of evidence suggests statins may in fact have a chemopreventive potential against cancer. AREAS COVERED IN THIS REVIEW: In this paper, we review evidence on the association between statin use and cancer risk. Specifically, we report on clinical trials and observational studies that measured all cancer or site-specific cancers of the breast, colorectal, lung, prostate and reproductive organs associated with statin use. WHAT THE READER WILL GAIN: An understanding of the evidence, including strengths and limitations, to support an association between statins and cancer. Information on the current state of the field and future directions are also discussed. TAKE HOME MESSAGE: Few strong or consistent associations between statins and cancer incidence overall or for any of the sites reviewed were detected. Data for any effects of statins on cancer prognosis and secondary prevention are lacking; with the exception of consistent evidence that statins are associated with reduced risk of advanced/aggressive prostate cancer. Statins appear safe in relation to cancer risk but any chemopreventive effect in humans remains to be established and should not be recommended outside the context of clinical trials. It is encouraging that numerous trials are ongoing. The prospect of reducing the incidence and burden of some of the most prevalent cancers with safe, affordable and tolerable medication that already reduces the risk of the leading cause of death and cardiovascular disease warrants further exploration in clinical trials and observational studies of prognosis and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · cited 2×
“002) [2], and total cancer and gastrointestinal cancer risk in another clinical trial [20].”
BackgroundDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Cited by
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Inflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Statin Use and Reduced Cancer-Related Mortality
(2013) · New England Journal of Medicine · doi:10.1056/nejmc1214827 · Cited by 720
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
“therefore be disruptive to cell cycle progression and cell proliferation (39, 40), thereby mediating anti-neoplastic effects (41, 42).”
BackgroundEzetimibe therapy: mechanism of action and clinical update
Toth, P., Phan, & Dayspring, T. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 288
Vazquez, A., Kamphorst, J. J., Markert, E. K., Schug, Z. T., Tardito, S., & Gottlieb, E. (2016) · Journal of Cell Science · doi:10.1242/jcs.181016 · Cited by 225
Mondul, A. M., Moore, S. C., Weinstein, S. J., Karoly, E. D., Sampson, J. N., & Albanes, D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29576 · Cited by 179
Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: A Cohort Study
Gagne, J. J., Choudhry, N. K., Kesselheim, A. S., Polinski, J. M., Hutchins, D., Matlin, O. S., Brennan, T. A., Avorn, J., & Shrank, W. H. (2014) · Annals of Internal Medicine · doi:10.7326/m13-2942 · Cited by 155
“Some observational studies have found an inverse association between statin use and cancer (38), but this has not been found in randomized, controlled trials (39) and other well-controlled observational studies (40, 41).”
Yarmolinsky, J., Bull, C. J., Vincent, E. E., Robinson, J., Walther, A., Smith, G. D., Lewis, S. J., Relton, C. L., & Martin, R. M. (2020) · JAMA · doi:10.1001/jama.2020.0150 · Cited by 124
“Statistical Analysis Mendelian randomization analysis assumes that the genetic instrument used to proxy a risk factor (1) is associated with the risk factor (“relevance”), (2) does not share a common cause with the outcome (“exchangeability”), and (3) affects the outcome only through the risk factor (“exclusion restri…”
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Nam, G.-H., Kwon, M., Jung, H., Ko, E., Kim, S. A., Choi, Y., Song, S. J., Kim, S., Lee, Y., Kim, G. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002474 · Cited by 82
Association of statin use with clinical outcomes in patients with triple‐negative breast cancer
Nowakowska, M. K., Lei, X., Thompson, M. T., Shaitelman, S. F., Wehner, M. R., Woodward, W. A., Giordano, S. H., & Nead, K. T. (2021) · Cancer · doi:10.1002/cncr.33797 · Cited by 62
Melanoma Chemoprevention: Current Status and Future Prospects
Chhabra, G., Ndiaye, M. A., Garcia‐Peterson, L. M., & Ahmad, N. (2017) · Photochemistry and Photobiology · doi:10.1111/php.12749 · Cited by 51
(2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.9.2553 · Cited by 44
“In the last two decades, the successful and widespread uses of statin drugs for hypercholesterolemia have revealed their potential anti-cancer effects (Boudreau et al., 2010).”
BackgroundLong-term use of anti-cholesterol drugs and cancer risks in a Japanese population
Okita, Y., Sobue, T., Zha, L., Kitamura, T., Iwasaki, M., Inoue, M., Yamaji, T., Tsugane, S., & Sawada, N. (2024) · Scientific Reports · doi:10.1038/s41598-024-53252-4 · Cited by 14
“Several reports have suggested that the mechanism of action of statins exerts a protective effect against cancers, independently from their effects on lowering cholesterol 7 , and some studies reported statins reduces risk to develop cancers 14,15 .”
BackgroundSimvastatin Attenuated Tumor Growth in Different Pancreatic Tumor Animal Models
Chen, C.-Y., Yang, Y.-F., Wang, P. C., Shan, L., Lin, S., Chen, P.-J., Chen, Y.-J., Chiang, H.-S., Lin, J.-T., Hung, C.-F., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15111408 · Cited by 13
“Lipid-lowering medicine (statin) has proved to be effective in the chemoprevention of other cancers [13].”
Background
Metadata
- Authors
- Boudreau, D. M., Yu, O., & Johnson, J.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2010-04-09
- Volume
- 9
- Issue
- 4
- Pages
- 603-621
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2072073513
- Cited by
- 274
- References
- 102
- FWCI
- 5.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.